Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the call transcript. The company remains net debt-free as of December 31, 2025, with cash and bank liquid investments of INR 826 crores. The company is planning capital expenditure of INR 450-500 crores for FY '27, but no mention of raising funds for this capex via debt or equity. Management indicated focus on increasing dividend payout but stated they are not looking at acquisitions, which often require external funding. Overall, no indication of any fundraising plans through debt or equity was provided in the

Any current/future capex/capital investment/strategic investment?

Planned capital expenditure (capex) for FY '26 is around INR 500 crores, with INR 399 crores already spent in the first 9 months. Capex is aimed at supporting a strong project pipeline, focusing on growth and resilience. For FY '27, capex guidance is estimated to be in the range of INR 450 crores to INR 500 crores, though it could be higher due to uncertainties. The capex primarily supports increasing the global registration pipeline of approximately 1,070 products. Registration timelines are uncertain and can vary widely from 1 year to up to 6-7 years. The company is not currently looking at

Future growth expectations in sales/revenue/volumes?

Expected volume growth of around 15% in FY '27. Revenue growth anticipated between 15% to 20% in FY '27. Q4 FY '26 projected as the strongest quarter with demand growth continuing. Growth driven by both new dealers and expanded geographic reach, especially in Europe. Price levels expected to improve gradually, supporting better margins. Strong pipeline with 1,076 product registrations in approval, supporting sustained future growth. Continued focus on increasing registrations and market penetration within key regions (Europe, NAFTA, LATAM). Capex planned in the range of INR 450-500 crores to s

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects volume growth of around 15% for FY '27. Revenue growth is anticipated to be in the range of 15% to 20% for FY '27. Gross margins of approximately 35% are sustainable and may even improve further in FY '27. EBITDA margins are expected to be maintained in the range of 18% to 20%. The company shows confidence in sustaining healthy EBITDA margins and improving overall profitability. PAT has demonstrated strong growth (366% YoY in Q3 FY '26) and the company aims to sustain growth momentum. Price realizations and product mix improvements are contributing to rising mar

Current/ Expected Orderbook/ Pending Orders?

As of December 31, 2025, Sharda Cropchem's total product registrations stand at 3,004 globally. There are 1,076 product registration applications currently in the approval pipeline. Regional breakup of pending registrations: Europe - 698, NAFTA - 100, LATAM - 153, Rest of the World - 125. Registration process timelines are uncertain; can range from 1-2 years to even 6-7 years due to regulatory complexities. The company is investing around INR 400-500 crores capex towards expanding registration pipeline and related capacities. These registrations form a critical part of their order book for fut

IN US

Sale is live|00:00:00left today

Sharda Cropchem LtdQ4 FY27Fertilizers & Agrochemicals

Sharda Cropchem Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹877P/E: 12.8Market Cap: ₹8.7K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Expected volume growth of around 15% in FY '27.
→Revenue growth anticipated between 15% to 20% in FY '27.
→Q4 FY '26 projected as the strongest quarter with demand growth continuing.
→Growth driven by both new dealers and expanded geographic reach, especially in Europe.
→Price levels expected to improve gradually, supporting better margins.
→Strong pipeline with 1,076 product registrations in approval, supporting sustained future growth.
→Continued focus on increasing registrations and market penetration within key regions (Europe, NAFTA, LATAM).
→Capex planned in the range of INR 450-500 crores to support growth and registration activities.

Margin guidance

Category 1

→The company expects volume growth of around 15% for FY '27.
→Revenue growth is anticipated to be in the range of 15% to 20% for FY '27.
→Gross margins of approximately 35% are sustainable and may even improve further in FY '27.
→EBITDA margins are expected to be maintained in the range of 18% to 20%.
→The company shows confidence in sustaining healthy EBITDA margins and improving overall profitability.
→PAT has demonstrated strong growth (366% YoY in Q3 FY '26) and the company aims to sustain growth momentum.
→Price realizations and product mix improvements are contributing to rising margins and revenues.
→Management expects gradual price increases, supporting better margins going forward.
→Dividend payouts are being considered for increase, indicating strong cash generation.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the call transcript.
→The company remains net debt-free as of December 31, 2025, with cash and bank liquid investments of INR 826 crores.
→The company is planning capital expenditure of INR 450-500 crores for FY '27, but no mention of raising funds for this capex via debt or equity.
→Management indicated focus on increasing dividend payout but stated they are not looking at acquisitions, which often require external funding.
→Overall, no indication of any fundraising plans through debt or equity was provided in the call.

Order book

→As of December 31, 2025, Sharda Cropchem's total product registrations stand at 3,004 globally.
→There are 1,076 product registration applications currently in the approval pipeline.
→Regional breakup of pending registrations: Europe - 698, NAFTA - 100, LATAM - 153, Rest of the World - 125.
→Registration process timelines are uncertain; can range from 1-2 years to even 6-7 years due to regulatory complexities.
→The company is investing around INR 400-500 crores capex towards expanding registration pipeline and related capacities.
→These registrations form a critical part of their order book for future revenue growth and market expansion.

Capex plans

Yes

→Planned capital expenditure (capex) for FY '26 is around INR 500 crores, with INR 399 crores already spent in the first 9 months.
→Capex is aimed at supporting a strong project pipeline, focusing on growth and resilience.
→For FY '27, capex guidance is estimated to be in the range of INR 450 crores to INR 500 crores, though it could be higher due to uncertainties.
→The capex primarily supports increasing the global registration pipeline of approximately 1,070 products.
→Registration timelines are uncertain and can vary widely from 1 year to up to 6-7 years.
→The company is not currently looking at acquisitions but is considering increasing dividend payouts instead.

How does Sharda Cropchem Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Sharda Cropchem Ltd

Rev 3Mar 1

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Sharda Cropchem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio